 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Trevena receives $15M non-dilutive tranche

Trevena receives $15M tranche under its ex-US royalty-based financing

$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena s partner in China New OLINVYK respiratory data from VOLITION...

Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant...

Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement

Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for...

Trevena Reports Second Quarter 2023 Results and Provides Business Update

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Trevena (TRVN Research Report), with a price target of $2... In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Trevena (TRVN &#8211...

JMP Securities Remains a Buy on Trevena (TRVN)

Trevena GAAP EPS of -$0.69, revenue of $3.02M

CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n=982) New respiratory data from VOLITION ~200 patient real-world outcomes ...

Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Femasys (FEMY Research Report) and Trevena (TRVN ... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Femasys (FEMY Research Report) and Trevena...

Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Trevena (TRVN)

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Watchers	25,983
52-Wk Low	$0.5369
52-Wk High	$5.13

Market Cap	$9.32M
Volume (M)	1.08M
52-Wk High	$5.13
52-Wk Low	$0.5369

TRVN Trevena Inc

About

Feed

News

Sentiment

Earnings

Fundamentals